series-c-plus
Stage
2018
Founded
6
Investors
About
Aura Biosciences is a clinical-stage biotechnology company developing precision therapies for solid tumors with the goal of preserving organ function; its lead candidate belzupacap sarotalocan (bel-sar, AU-011) is in a global Phase 3 trial for early choroidal melanoma and is being evaluated in other ocular oncology indications and bladder cancer.
Explore Aura Biosciences's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.